ASCO 前列腺癌筛查/预后评估相关进展亮点精粹

参考文献

[1] Eeles RA, et al. Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results. 2024 ASCO 10500.

[2] Nguyen CB, et al. Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC). 2024 ASCO 5085.

[3] Azad A, et al. Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ASCO 5020.

[4] Halabi S, et al. A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance). 2024 ASCO 5007.